About the Authors

Xiang Ling

Contributed equally to this work with: Xiang Ling, Shousong Cao

Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Shousong Cao

Contributed equally to this work with: Xiang Ling, Shousong Cao

Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Qiuying Cheng

Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America

James T. Keefe

Affiliation Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Youcef M. Rustum

Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, NCI-supported Experimental Therapeutics Program, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Fengzhi Li

fengzhi.li@roswellpark.org

Affiliations Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, United States of America, NCI-supported Experimental Therapeutics Program, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Competing Interests

FL118 will be further developed in Canget BioTekpharma (www.canget-biotek.com), a Roswell Park Cancer Institute (RPCI) spinoff company founded by the PI. Otherwise, there is no conflict of interest.

Author Contributions

Conceived and designed the experiments: XL SC YMR FL. Performed the experiments: XL SC QC JTK FL. Analyzed the data: XL SC. Contributed reagents/materials/analysis tools: SC YMR FL. Wrote the paper: FL. Read and revised the manuscript: XL SC QC JTK YMR FL.